Physician profile
Jen C Wang
NPI 1205938115
$25,287.70
in general payments reported to CMS, 2019-2025
61 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,646 · 2020: $2,556 · 2021: $3,120 · 2022: $2,620 · 2023: $3,299 · 2024: $3,381 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,739 · Education: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,739.45 |
| Education | $606.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $4,656.44 | 2019-2025 | Reblozyl |
| Janssen Biotech, INC. | $3,202.76 | 2019-2025 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $2,480.57 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,743.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,523.58 | 2019-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $1,400.61 | 2019-2025 | Jakafi, Monjuvi, Monjuvi |
| Merck Sharp & Dohme LLC | $1,195.15 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Genzyme Corporation | $896.28 | 2019-2025 | |
| Astellas Pharma US INC | $628.26 | 2019-2025 | Xtandi, Xospata, Padcev |
| Pfizer INC. | $546.33 | 2019-2025 | |
| Puma Biotechnology, INC. | $505.62 | 2019-2025 | Nerlynx |
| Seagen INC. | $462.58 | 2020-2023 | Padcev, Adcetris, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $427.43 | 2019-2024 | |
| Lilly USA, LLC | $406.12 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $397.23 | 2020-2024 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.